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The large family of chemoattractant cytokines (chemokines) embraces multiple, in part
unrelated functions that go well beyond chemotaxis. Undoubtedly, the control of immune
cell migration (chemotaxis) is the single, unifying response mediated by all chemokines,
which involves the sequential engagement of chemokine receptors on migrating target
cells. However, numerous additional cellular responses are mediated by some (but not all)
chemokines, including angiogenesis, tumor cell growth, T-cell co-stimulation, and control
of HIV-1 infection. The recently described antimicrobial activity of several chemokines is
of particular interest because antimicrobial peptides are thought to provide an essential
first-line defense against invading microbes at the extremely large body surfaces of the
skin, lungs, and gastrointestinal-urinary tract. Here we summarize the current knowledge
about chemokines with antimicrobial activity and discuss their potential contribution to
the control of bacterial infections that may take place at the earliest stage of antimicro-
bial immunity. In the case of homeostatic chemokines with antimicrobial function, such as
CXCL14, we propose an immune surveillance function in healthy epithelial tissues char-
acterized by low-level exposure to environmental microbes. Inflammatory chemokines,
i.e., chemokines that are produced in tissue cells in response to microbial antigens (such
as pathogen-associated molecular patterns) may be more important in orchestrating the
cellular arm in antimicrobial immunity.
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INTRODUCTION
Antimicrobial peptides (AMPs) are components of the innate
immune system and are particularly important in the control of
cutaneous and intestinal immune defenses (Lai and Gallo, 2009).
Underscoring their importance, many AMPs are produced early in
phylogenesis, being already present in non-vertebrates, and they
exhibit substantial sequence conservation throughout evolution.
Initial evidence of host-derived peptides with antimicrobial activ-
ities was reported in 1963 in a study describing the discovery of
bactericidal basic proteins in the lysosomal granules of polymor-
phonuclear leukocytes (Zeya and Spitznagel, 1963). Most AMPs
are small proteins with less than 50 amino acid residues. More
than 800 AMPs have been described since the initial discovery,
and among these the defensins and the cathelicidin LL-37 are con-
sidered to be the major AMPs present in humans (see reviews,
Ganz, 2003; Izadpanah and Gallo, 2005; Cederlund et al., 2011).
Defensins and LL-37 are active against a broad spectrum of Gram-
negative and Gram-positive bacteria, fungi, and viruses. In line
with their antimicrobial activity, they are produced mainly by
tissue macrophages and epithelial cells including keratinocytes,
Paneth cells, and mucosal epithelial cells but are also present in
tissues that are not exposed to exterior microbes. These AMPs are
structurally related and positively charged at neutral pH (high pI
values), and they have the ability to form clusters of hydrophobic
and cationic amino acids in aqueous solutions. It is thought that
such amphipathic aggregates bind to negatively charged surfaces of
microbes leading to membrane disruption and loss of intracellular
constituents (Ganz, 2003; Brogden, 2005). In addition to defensins
and cathelicidins, there are other AMPs, such as RNAse 7,psoriasin,
granulysin, dermcidin, or C-type lectins (Wiesner and Vilcinskas,
2010). Their mechanism of antimicrobial action is not well char-
acterized, but seems to be different from that of the defensins
(Mukherjee et al., 2008). More recently,members of the chemokine
family were also found to act as AMPs, and one of the first and best
characterized “AMP chemokine” is CCL20 (Hoover et al., 2002).
Of note, the overall tertiary structure of chemokines defined by
disulfide bonds, anti-parallel β-strands, and a C-terminal α-helix
is very similar to the one seen in defensins (Figure 1). Even LL-
37, the active part of the cathelicidin, shares striking structural
similarities with the C-terminal α-helix of chemokines. In addi-
tion, similar to defensins and cathelicidins, many chemokines are
highly positively charged at neutral pH, which may further explain
their antimicrobial activity. Finally, chemokines are also known to
form dimers and multimeric aggregates leading to elevated local
concentrations (Proudfoot et al., 2003). Of interest, cationic AMPs
share functional properties with chemokines, such as chemotactic
activity (Yang et al., 1999; Agerberth et al., 2000; De et al., 2000; Wu
et al., 2003; Soruri et al., 2007) and were reported to participate
in inflammation, wound healing, and adaptive immune responses
(Heilborn et al., 2003; Niyonsaba et al., 2007).
The discovery that members of the chemokine family have AMP
activity, in addition to their prototype chemoattractant functions,
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FIGURE 1 | Structural characteristics predict CXCL14 as an
antimicrobial peptide. (A) CXCL14 has structural similarities to both the
defensin family (anti-parallel β-sheets) and the cathelicidins (C-terminally
located α-helix). In addition, antimicrobial peptides and CXCL14 comprise
high pI values. (B) CXCL14 exhibits high amino acid sequence
conservation throughout evolution; 97.4% identity with mouse, 63.6%
both with chicken and fish. Red arrow heads denote cationic amino acid
residues.
suggests a key role in the control of antimicrobial immunity and
merits a more detailed discussion. Simplistically, chemokines are
divided into two functional groups: the“homeostatic”chemokines
present at distinct locations throughout the body, and “inflamma-
tory” chemokines that are induced locally in response to infection
and inflammation (Moser et al., 2004). Members of both groups
were shown to display in vitro AMP activity, suggesting their
involvement not only at the earliest stages of infection but also
during the inflammatory phase of antimicrobial immunity. Con-
sequently, one may propose that one function of homeostatic AMP
chemokines produced in healthy peripheral tissues is meant to
contain microbes in order to prevent the onset of an inflammatory
cascade (and associated tissue damage) in response to low dose
microbial exposures. Inflammatory AMP chemokines on the other
hand act in concert with recruited immune cells in response to sub-
stantial microbial infections. Therefore, homeostatic and inflam-
matory AMP chemokines may target asymptomatic (“unno-
ticed”) and symptomatic (“inflammatory”) infections, respec-
tively. Before discussing AMP chemokines we will summarize the
structure, production, and functions of classical AMPs.
“CLASSICAL” (NON-CHEMOKINE) AMPs
Antimicrobial peptides constitute a primordial immune defense
mechanism operating in both vertebrate and invertebrate
organisms (Zasloff, 2002). The detailed mechanisms underlying
bacterial killing are not fully understood. However, based on their
net positive charges, the cationic AMPs are suggested to interact
with the negatively charged membranes of bacteria via electro-
static interaction. The amphipathic moieties in AMP aggregates
facilitate their insertion into the bacterial membrane, which even-
tually leads to membrane permeabilization, leakage of ions, and
consequently bacterial cell death (Brogden, 2005; Wiesner and
Vilcinskas, 2010). In the following section, we briefly discuss
the most important “classical” AMPs found in humans. Partic-
ularly abundant in humans (and mammals) are the defensins
and the cathelicidins, and their impact in immune defense are
excellently summarized in a recent review (Lai and Gallo, 2009).
The defensins have molecular masses between 3.5 and 6.0 kDa,
are positively charged and contain six cysteine residues that form
three intramolecular disulfide bridges (Ganz, 2003; Lehrer, 2004;
De Smet and Contreras, 2005). On the basis of the size and the
disulfide arrangement, the defensins are divided into two sub-
families: the α-defensins and β-defensins. In humans, six different
α-defensins and four β-defensins have been identified and char-
acterized. The α-defensins HNP-1 to HNP-4 (originally named
human neutrophil proteins) are stored in azurophilic granules of
neutrophils where they constitute upto 50% of the proteins. The
α-defensins HD-5 and HD-6 (stands for human defensin) on the
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other hand, are produced specifically by intestinal Paneth cells
(Rehaume and Hancock, 2008). The human β-defensins (hBD)-1
to hBD-4 are mainly synthesized by epithelial cells at diverse body
surfaces such as skin, intestine, or trachea (Ganz, 2003). Catheli-
cidins are synthesized as inactive propeptides with a conserved N-
terminal region that is proteolytically removed to liberate the active
peptide. In humans, only one cathelicidin is produced, the propep-
tide hCAP-18 which is enzymatically processed by serine proteases
from neutrophil granules (Sorensen et al., 2001) or keratinocytes
(Yamasaki et al., 2006) into an active peptide of 37 amino acids (LL-
37; Zanetti, 2004). Moreover, LL-37 can be processed to smaller
peptides with potent antimicrobial activity such as RK-31 and
KS-30 (Murakami et al., 2004). Of note, and in contrast to the“salt-
sensitive” defensins, LL-37 was reported to be also active (albeit to
a lesser degree) at high sodium chloride concentrations such as
frequently encountered in the skin (Travis et al., 2000; Frick et al.,
2006). The list of “classical” AMPs includes many other struc-
turally unrelated peptides and proteins such as enzymes, enzyme
inhibitors, neuropeptides, or complement-derived peptides (Lai
and Gallo, 2009; Wiesner and Vilcinskas, 2010).
Due to constant microbial exposure, skin, and gastrointestinal
body surfaces are principal sites of AMP expression. More than
20 AMPs are known to be present in human skin, and the most
important of them belong to the molecular families of defensins
and cathelicidins as discussed above or are RNases, S100 proteins,
or neuropeptides (Schauber and Gallo, 2009). The skin AMPs are
either constitutively expressed by epidermal keratinocytes or are
induced in response to skin infection or tissue damage. The human
cathelicidin proprotein (hCAP-18) and precursor of the active
LL-37 is not expressed in healthy human skin, but is induced by
inflammatory or infectious stimuli (Frohm et al., 1997). Vitamin
D3 metabolites, constitutively produced in the skin during expo-
sure to UVB radiation, are also inducers of cathelicidin production
(Liu et al., 2006; Schauber and Gallo, 2008). LL-37 shows in vitro
antimicrobial activity at micromolar concentrations against a wide
range of both Gram-negative (P. aeruginosa, S. typhimurium, E.
coli) and Gram-positive (S. aureus, S. epidermidis, and L. mono-
cytogenes) bacteria and fungi. Production of defensins in the skin
happens both under steady-state and inflammatory conditions.
hBD-1 was shown to be constitutively expressed, whereas the
expression of hBD-2 and hBD-3 is induced in keratinocytes by pro-
inflammatory cytokines and, importantly, by microbes-derived
pathogen-associated molecular patterns (Ganz, 2003). Dermcidin,
a 47-residue AMP, is constitutively produced by eccrine glands and
represents the principal antimicrobial peptide in sweat (Schittek
et al., 2001). Importantly, in contrast to most other AMPs, derm-
cidin is not affected by low pH and increased salt concentrations,
conditions that are typically found in sweat (Schittek et al., 2001).
A major AMP of healthy human skin, but also of tonsils and
pharynx is RNAse 7 (Harder and Schroder, 2002; Zasloff, 2009).
RNAse 7 exhibits broad spectrum antimicrobial activity at low
micromolar concentrations against both Gram-negative (E. coli
and P. aeruginosa) and Gram-positive (Propionibacterium acnes, S.
aureus) bacteria and the yeast C. albicans. Similar to hBD-2 and
hBD-3, RNAse 7 expression in primary keratinocytes is induced by
pro-inflammatory conditions and microbial stimuli (Harder and
Schroder, 2002). Psoriasin, identified as the main “E. coli killing
factor”, is an 11-kDa protein with preferential expression in the
uppermost layer (stratum corneum) of the epidermis (Glaser et al.,
2005). Elevated levels of psoriasin were further described in dis-
eased skin, such as atopic dermatitis (AD) and psoriasis (Simanski
et al., 2010).
Because several cutaneous AMPs are sensitive to elevated
sodium chloride concentrations, it remained speculative whether
they play a major role in local immune defense. However, experi-
mental evidence supports a corresponding function since absence
or malfunction of cutaneous AMPs are often correlated with skin
disease (Lai and Gallo, 2009). For instance, mice deficient in the
CRAMP-gene, the mouse homolog of human LL-37, were more
susceptible to skin infections caused by group A Streptococcus, suf-
fered from a delay in wound healing and also had more severe
urinary tract infections than their wild type counterparts (Nizet
et al., 2001; Chromek et al., 2006). Mice deficient in β-defensin-
1 (mBD-1) showed impaired clearance of S. aureus in the lungs
and urinary tract compared to wild type (Morrison et al., 2002;
Moser et al., 2002). Likewise, altered levels of AMPs appear to play
a role in the susceptibility to infections in patients with chronic
inflammatory skin disorders. Substantial up-regulation of LL-37
and hBD-2 production was observed in psoriasis (Frohm et al.,
1997). In agreement with a role for these peptides in antimicrobial
immunity, psoriasis lesions are rarely infected, which is in clear
contrast to AD lesions characterized by base-level AMP produc-
tion and frequent bacterial infections in their excemas (Ong et al.,
2002; Nomura et al., 2003). LL-37 production was also found to be
upregulated in neonatal skin, which may be viewed as a compen-
satory mechanism for lack of an effective cellular antimicrobial
immune system in newborns (Dorschner et al., 2003). Further-
more, changes in hBD-1 activity have been linked to the lung
pathogenesis of cystic fibrosis (CF; Goldman et al., 1997). The pul-
monary mucosa of CF patients is often colonized by P. aeruginosa
which may be neutralized in part by local AMPs. Although AMP
knock-down experiments in humans cannot be performed, it is
now generally accepted that AMPs contribute to the local antimi-
crobial immune responses. The emerging view supports the notion
whereby inducible AMPs rather than those present in healthy tis-
sues contribute to the clearance of microbes at sites of chronic
inflammatory diseases.
In addition to the antimicrobial activity, several AMPs exhibit
immunoregulatory properties, including chemotactic activity for
immune cells. LL-37 interacts with the formyl peptide receptor like
receptor FPRL-1 and mediates chemotaxis of neutrophils, mono-
cytes, and CD4+ T-cells (Agerberth et al., 2000; De et al., 2000).
Intriguingly, FPRL-1 does not seem to be involved in LL-37 medi-
ated migration of mast cells (Niyonsaba et al., 2002). Moreover,
hBD-1, -2, and -3 were reported to bind to CCR6, the receptor for
CCL20, and to mediate chemotactic responses in immature den-
dritic cells and memory T-cells (Yang et al., 1999). However, this
finding has been disputed by others (Soruri et al., 2007). hBD-3
was also reported to interact with CXCR4 (Feng et al., 2006), and to
be a chemoattractant for monocytes, which do not express CCR6
(Wu et al., 2003). Finally, several reports describe the chemoat-
tractant activity of α-defensins (Yang et al., 2000; Grigat et al.,
2007; Rehaume and Hancock, 2008). In addition to immune cell
migration, AMPs were also described to affect alternative cellular
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responses as diverse as cell proliferation, wound healing, angiogen-
esis, and the release of cytokines and histamine (Bals and Wilson,
2003; Heilborn et al., 2003; Davidson et al., 2004; Niyonsaba et al.,
2007; Rehaume and Hancock, 2008).
CHEMOKINES ACTING AS AMPs
The first report describing chemokines with antimicrobial func-
tion appeared in 2000 (Krijgsveld et al., 2000). The authors iden-
tified two antibacterial proteins in platelet granules and showed
them to be variants of CXCL7 (NAP-2) and CTAP-3, respec-
tively, that lacked the two C-terminal amino acids (Ala-Asp).
Of interest, the intact proteins did not display antimicrobial
activity, pointing to the importance of the C-terminal regions
as will be discussed in Section “Structure-Function Considera-
tions of Chemokine-AMPs.” Subsequently, additional reports of
chemokines with antimicrobial activity appeared in rapid suc-
cession, providing evidence that antimicrobial activity is not an
exceptional feature of only a few chemokines. Based on struc-
tural consideration, i.e., secondary structure similarities between
chemokines and defensins (Territo et al., 1989; Chertov et al., 1996;
Yang et al., 1999), the non-ELR chemokines CXCL9, CXCL10, and
CXCL11 were tested in vitro in E. coli and L. monocytogenes killing
assays and found to be potent AMPs (Cole et al., 2001). These
authors further demonstrated that CXCL8, CXCL5, CCL2, CCL3,
CCL4, CCL5, CX3CL1, and XCL1 were all inactive in the respective
in vitro assays. Subsequently, J. Oppenheim and colleagues carried
out an almost complete screen of human chemokines and reported
that, indeed, chemokines with antimicrobial activity are not rare
(Yang et al., 2003). Based on unifying structure and electrosta-
tic features, the authors concluded that antimicrobial chemokines
share several positively charged surface patches that seemed to be
required for antimicrobial activity.
The findings of numerous additional studies that followed these
initial reports are summarized in Table 1 (including respective
references). Of a total of 45 human chemokines, 23 (10 CXC
and 13 CC chemokines) were reported to exhibit antimicrobial
activity. It is important to note that several reports remained con-
troversial, i.e., could not be reproduced by other laboratories,
which, probably, is due to differences in the selected experi-
mental procedures (bacterial species, bacterial culture conditions,
conditions for liquid culture killing and radial diffusion assays,
etc.). For example, CXCL6 was found by some groups to be a
potent AMP against several Gram-negative and Gram-positive
bacteria (Collin et al., 2008; Linge et al., 2008) whereas earlier
experiments performed by another group did not support this
conclusion (Yang et al., 2003). In contrast to the chemotactic prop-
erties of chemokines, which are specific for leukocytes bearing the
corresponding chemokine receptors, no specific pattern for the
antimicrobial activity has been detected so far. In fact, chemokine-
mediated bacterial killing is completely unrelated to chemokine
receptor specificity and appears to involve protein structures that
are different from chemokine receptor-binding motifs.
Most studies exploring antimicrobial activities of chemokines
have been limited to in vitro investigations and very few data con-
clusively support a role as AMPs in in vivo infection models. One
of the difficulties associated with in vivo studies is the fact that
chemokines induce the recruitment of leukocytes, whose cellular
responses against microbes may obscure their bonafide AMP func-
tion. Importantly, in most in vitro studies chemotactic responses
were elicited at >10-fold lower chemokine concentrations than
what were required for AMP activity. In vivo relevance of the
importance of AMPs in host defense however has been demon-
strated with the model of B. anthracis infection. In a first study,
Crawford et al. (2009) have shown that germination of B. anthracis
spores can be inhibited by CXCL10. They established a correla-
tion between higher levels of CXCL9, CXCL10, and CXCL11 in
the lungs of C57BL/6 mice and the resistance of these mice to
respiratory B. anthracis infection and showed that A/J mice whose
lungs expressed considerably lower levels of these chemokines were
highly susceptible to B. anthracis infection. Further investigations
supported these data by showing that C57BL/6 mice pretreated
with CXCL9-, CXCL10-, or CXCL11-neutralizing antibodies were
more susceptible to B. anthracis infection and that this effect was
independent of the chemokine receptor CXCR3 (Crawford et al.,
2010).
STRUCTURE-FUNCTION CONSIDERATIONS OF
CHEMOKINE-AMPs
As already briefly mentioned, structural analysis of chemokines
and defensins revealed that these two peptide families share struc-
tural motifs that may explain their common AMP activities. Most
of the structure-function studies involved the comparison between
the best described AMP chemokine, CCL20 with hBD-1 and hBD-
2 (Hoover et al., 2002; Chan et al., 2008). The homology of these
peptides, however, does not lie in the amino acid sequence but
is confined to structural features such as cationic residues and
amphipathic stretches that are frequent in the COOH-terminal
α-helices of the classical AMPs. Peptides with cationic residues
and amphipathic stretches have been shown to adopt a helical
structure in a membrane mimetic solvent, for example in a 2,2,2-
trifluoroethanol/water mixture (Nguyen et al., 2010). In some
cases the AMP activity of the C-terminus is hidden by intramol-
ecular interactions, which may neutralize the positively charged
C-terminal α-helix (Nguyen et al., 2010). Intramolecular inter-
action may also explain why C-terminal peptides but not the
intact molecule of CXCL8 displays antimicrobial activity (Bjorstad
et al., 2005). This also suggests that proteolytic processing of some
mature chemokines may be required to convert them into potent
AMPs. It is noteworthy that at present we have no idea about
the type of protease(s) responsible for converting inflammatory
chemokines into AMPs. By contrast, two recent studies demon-
strate that bacterial proteases degraded chemokines into inactive
peptides (Egesten et al., 2009; Frick et al., 2011), thereby revealing
a strategy of pathogens to avoid innate immune mechanism(s) of
the host. Such escape mechanisms of bacteria are also known to
inactivate classical AMPs, such as LL-37 and dermcidin (Lai and
Gallo, 2009). Interestingly, the M1 strain of S. pyogenes secretes
the protein “Streptococcal Inhibitor of Complement” (SIC) that
was shown to block the AMP activity of CXCL9 (Egesten et al.,
2007). It appears that the negatively charged SIC competes with
glycosaminoglycans (GAGs) for binding to the positively charged
CXCL9, suggesting an important role of CXCL9-GAGs interac-
tions on epithelial surfaces for controlling antimicrobial activity.
Furthermore, as reported for CXCL9 (Egesten et al., 2011), plasma
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Table 1 | Antimicrobial activities of chemokines.
Chemokine Receptor Function Microbial targets (activity) Reference
NATURAL CHEMOKINES WITH ANTIMICROBIAL ACTIVITY
CXCL1/GROα CXCR2 Inflammatory E. coli (10µg/ml: 65–87% killed) Yang et al. (2003)
CXCL2/GROβ CXCR2 S. aureus (10µg/ml: 22–39% killed)
CXCL3/GROγ CXCR2
CXCL6/GCP-21 CXCR1/R2 Inflammatory N. gonorrhoeae (1µM: 60% killed) Collin et al. (2008)
E. faecalis (1µM: 100% killed) Linge et al. (2008)
S. pyogenes (MBC290: 0.30)
S. dysgalactiae (MBC90: 0.28)
S. aureus (MBC90: 0.59)
E. coli (MBC90: 0.46)
P. aeruginosa (MBC90: 0.96)
CXCL71–68 (=TC-1)3 CXCR2 B. subtilis (MBC100: 0.4–0.7) Krijgsveld et al. (2000)
PBP410–92 (=TC-2) S. aureus (MBC100: 6.8–11.0)
E. coli (MBC100: 2.7–3.4)
CXCL9/MIG CXCR3 Inflammatory E. coli (MIC5: 0.5 (CXCL9), 4.4 (CXCL10),
6.5 (CXCL11)
Cole et al. (2001)
CXCL10/IP-10 CXCR3 L. monocytogenes (MIC: 3.6 (CXCL9), 7.0
(CXCL10), 8.0 (CXCL11)
Yang et al. (2003)
CXCL11/I-TAC CXCR3/R7 E. coli (10µg/ml: 72–100% killed)6 Crawford et al. (2009)
S. aureus (10µg/ml: 69–81% killed) Crawford et al. (2010)
B. anthracis spores [EC50; µg/ml: 6.2
(CXCL9), 7.9 (CXCL10), 28.2 (CXCL11)]
Egesten et al. (2007)
S. pyogenes [EC50; µM: 0.022 (CXCL9),
0.17 (CXCL10 and CXCL11)]
CXCL12/SDF-1 CXCR4/R7 Homeostatic E. coli (10µg/ml: 86% killed) Yang et al. (2003)
S. aureus (10µg/ml: 59% killed)
CXCL13/BCA-1 CXCR5 Homeostatic E. coli (10µg/ml: 83% killed) Yang et al. (2003)
S. aureus (10µg/ml: 50% killed)
CXCL14/BRAK Unknown Homeostatic E. coli (10µg/ml: 50% killed) Yang et al. (2003)
S. aureus (10µg/ml: 35% killed) Frick et al. (2011)
S. pyogenes (1µM: 100% killed) Maerki et al. (2009)
F. magna (1µM: 100% killed)
E. coli (MIC: 0.32) Maerki et al. (2009)
S. coag.neg. (MIC: 1.02)
S. aureus (MIC: 5.17)
Propionibact. (MIC: 1.16)
C. albicans (MIC: 0.56)
XCL1/lymphotactin7 XCR1 E. coli (10µg/ml: 100% killed) Yang et al. (2003)
S. aureus (10µg/ml: 47% killed)
CCL1/I-309 CCR8 Homeostatic E. coli (10µg/ml: 88% killed) Yang et al. (2003)
S. aureus (10µg/ml: 37% killed)
CCL2/MCP-17 CCR2/R4 Inflammatory E. coli (LD90: 30µg/ml) Hoover et al. (2003)
CCL11/Eotaxin CCR3 Inflammatory E. coli (10µg/ml: 66% killed) Yang et al. (2003)
S. aureus (10µg/ml: 49% killed)
CCL13/MCP-48 CCR2/R3 Inflammatory E. coli (10µg/ml: 76% killed) Yang et al. (2003), Martinez-
Becerra et al. (2007)
CCL14 CCR1 Inflammatory E. coli (1µM: 60% killed) Kotarsky et al. (2010)
CCL15 CCR1/R3
CCL17/TARC CCR4 Inflammatory E. coli (10µg/ml: 59% killed) Yang et al. (2003)
S. aureus (10µg/ml: 46% killed)
CCL18/PARC Homeostatic E. coli (10µg/ml: 100% killed) Yang et al. (2003)
S. aureus (10µg/ml: 69% killed)
(Continued)
www.frontiersin.org July 2012 | Volume 3 | Article 213 | 5
Wolf and Moser Antimicrobial activities of chemokines
Table 1 | Continued
Chemokine Receptor Function Microbial targets (activity) Reference
CCL19/ELC8 CCR7 Homeostatic E. coli (10µg/ml: 82% killed) Yang et al. (2003)
CCL20/LARC CCR6 Inflammatory E. coli (LD50: 0.4µg/ml,) Yang et al. (2003)
S. aureus (LD50: 10µg/ml) Hoover et al. (2002)
C. albicans (LD50: 25µg/ml) Kim et al. (2007)
S. pyogenes (LD50: 0.2µg/ml)
E. faecium (LD50: 4.5µg/ml)
P. aeruginosa (LD50: 1.1µg/ml)
M. catarrhalis (LD50: 0.9µg/ml)
Vaccinia virus
CCL21/SLC CCR7 Homeostatic E. coli (10µg/ml: 45% killed) Yang et al. (2003)
S. aureus (10µg/ml: 75% killed)
CCL22/MDC CCR4 Inflammatory E. coli (10µg/ml: 100% killed) Yang et al. (2003)
S. aureus (10µg/ml: 74% killed)
CCL25/TECK CCR9 Homeostatic E. coli (10µg/ml: 68% killed) Yang et al. (2003)
S. aureus (10µg/ml: 48% killed)
CCL28/MEC CCR3/R10 Inflammatory C. albicans (IC50: 0.7µM) Hieshima et al. (2003)
P. aeruginosa (IC50: 0.4µM)
S. mutans (IC50: 1.7µM)
S. aureus (IC50: 0.9µM)
S. pyogenes (IC50: 3.0µM)
K. pneumoniae (IC50: 0.3µM)
CHEMOKINES WITHOUT ANTIMICROBIAL ACTIVITY9
CXCL5/ENA-78 CXCR2 Inflammatory E. coli, S. aureus, C. albicans Yang et al. (2003)
CXCL6/GCP-210 CXCR1/R2 Cole et al. (2001)
CXCL7/NAP-2 CXCR2 Maerki et al. (2009)
CXCL8/IL-8 CXCR1/R2
CX3CL1/Fractalkine CX3CR1/R2
CCL2/MCP-111 CCR2/4 Inflammatory E. coli, S. aureus, B. anthracis spores, P.
aeruginosa, S. mutans
Yang et al. (2003)
CCL3/MIP-1α CCR1/R4/R5 Cole et al. (2001)
CCL4//MIP-1β CCR5 Crawford et al. (2009)
CCL5/RANTES CCR1/R3/R4/R5 Crawford et al. (2010)
CCL7/MCP-3 CCR1/R2/R3 Hieshima et al. (2003)
CCL16/HCC-4 CCR1 Liu and Wilson (2010)
CCL27/CTACK CCR10
CHEMOKINE-DERIVED PEPTIDES WITH ANTIMICROBIAL ACTIVITY
CXCL750–7012 B. subtilis (LD99.9>120µM) Nguyen et al. (2010)
CXCL750–68 (=TC-150–68) S. aureus (LD99.9>120µM)
E. coli (LD99.9>120µM)
CXCL880–9913 E. coli (LD99.9>120µM) Nguyen et al. (2010)
CXCL881–99 K. pneumoniae Bjorstad et al. (2005)
CXCL853–72 S. pyogenes
H. pylori
E. enterica MR10
B. subtilis (LD99.9>120µM)
S. aureus (LD99.9>120µM)
CXCL979–105 S. pyogenes (ED50: 0.02µM) Egesten et al. (2007)
CCL1357–75 (=CDAP-4) E. coli (6.8µM: 47% killed) Martinez-Becerra et al. (2007)
P. aeruginosa (6.8µM: 91% killed)
S. typhi (6.8µM: 84% killed)
S. typhimurium (6.8µM: 91% killed)
K. pneumonia (6.8µM: 47% killed)
(Continued)
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Table 1 | Continued
Chemokine Receptor Function Microbial targets (activity) Reference
CCL2051–70 E. coli (MIC: 12.5µg/ml;
LD99.9 ≤0.45µM)
Nguyen et al. (2010)
CCL2059–70 S. aureus (MIC: 63µg/ml; LD99.9: 1.9µM) Chan et al. (2008)
B. subtilis (LD99.9 ≤0.45µM) Hasan et al. (2006)
E. coli (LD50: 3.2µg/ml); (LD99.9: 30µM)
B. subtilis (LD99.9: 15µM)
CCL2877–10514 S. aureus (IC50: 7.0µM) Hieshima et al. (2003)
C.albicans (IC50: 1.6µM) Liu and Wilson (2010)
P. aeruginosa
1No activity with C. albicans; inactive in Yang et al. (2003).
2MBC90, minimal bactericidal concentration to kill 90% of bacteria, µM.
3Full-size CXCL71–70 has no activity.
4Platelet Basic Protein.
5MIC, minimal inhibitory concentration, µM.
6Crawford et al. (2010) shows in vivo evidence.
7Inactive in Cole et al. (2001).
8No activity with S. aureus.
9Tested, but not found to be active.
10CXCL6 is reported as active in Yang et al. (2003), Collin et al. (2008).
11CCL2 is reported as active in Hoover et al. (2003).
12Full-size CXCL71–70 has no activity.
13Full-size CXCL8 has no activity.
14Positively charged C-terminus essential, but not sufficient.
proteins may also indirectly inhibit antimicrobial activity by bind-
ing to the cell wall proteins of bacteria, thereby interfering with
the binding of AMPs.
Initial structure-function studies assumed that the disulfide
bonds are essential for antimicrobial activity. However, recent
work revealed that hBD-1, known as an AMP with low antimi-
crobial activity, turned into a potent AMP following reduction of
its disulfide bonds (Schroeder et al., 2011). hBD-1 has restricted
specificity for Gram-negative bacteria, but acquired broad spec-
trum antimicrobial activity against anaerobic Gram-positive bac-
teria and C. albicans, upon reduction of the disulfide bonds. The
importance of disulfide bonds does not apply to all AMPs because
mutations of cysteine residues in CCL28 (Liu and Wilson, 2010)
or hBD-3 (Wu et al., 2003), did not affect their AMP.
Today, the AMP activity of several chemokines is firmly estab-
lished although the underlying mechanism(s) remain ill defined.
On the basis of structural considerations (Yang et al., 2003), most
laboratories have assumed that cationic chemokines attack bac-
terial membranes similar to cationic and amphipathic defensins.
In agreement, several reports demonstrate that chemokines bind
to bacteria and induce leakage of intracellular contents, as shown
for CXCL14 (Frick et al., 2011) and CXCL6/GCP-2 (Linge et al.,
2008). Furthermore, full-length CXCL6 was compared with dele-
tion variants composed of either the C-terminal 19 amino acids or
the NH2-terminal 50 amino acids. Both variant peptides displayed
lower antimicrobial activity than the full-length CXCL6. However,
the NH2-terminal peptide was the more potent of the two variant
peptides and was able to induce in sodium chloride-sensitive fash-
ion membrane damage in carboxyfluorescein-loaded liposomes.
In contrast, other studies concluded that the membrane attack
is not the principal killing mechanism. For instance, the CXCL7
derivatives TC-1 or TC-2 inhibited several bacterial species but did
not act on bacterial membranes, as evidenced by lack of changes in
membrane potential (Krijgsveld et al., 2000). Also, CCL6 induced
only partial membrane depolarization, a further sign that alter-
native mechanisms may contribute to the observed antimicrobial
activity (Kotarsky et al., 2010).
Comparing hydrophobicity regions in ELR chemokines with
those of non-ELR chemokines, Cole et al. (2001) reported that
most notable differences reside in the C-terminal helices, which
are more polar and positively charged in non-ELR chemokines.
Accordingly, the non-ELR chemokines CXCL9, CXCL10, and
CXCL11 were found to display antimicrobial activity whereas
the ELR chemokines CXCL5 and CXCL8 failed to do so. Along
the same line, the last five C-terminal amino acids (Arg-Lys-
Asp-Arg-Lys) in CCL28 were found to be essential for bacte-
rial killing (Liu and Wilson, 2010). Mutant chemokines miss-
ing these five amino acids or variants where the arginine was
replaced by the neutral alanine or the negatively charged aspar-
tate had diminished AMP activity. Moreover, these authors
demonstrated that the C-terminal region by itself was inac-
tive and that full activity depended on NH2-terminal regions
(either supplied by CCL28 or by CCL5 in chimeric chemokine
constructs). Of note, the structures responsible for antimicro-
bial activity differ from those involved in controlling leuko-
cyte chemotaxis (Clark-Lewis et al., 1994). In conclusion, more
work is required to fully understand the structures involved
in bacterial killing, which may lead to engineered chemokine
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variants with improved antimicrobial activity suitable for clini-
cal use.
HUMAN CXCL14: AN EXAMPLE OF A BROAD SPECTRUM
ANTIMICROBIAL CHEMOKINE
Our group has a special interest in CXCL14, one of the most
recent chemokines (Hromas et al., 1999; Frederick et al., 2000;
Sleeman et al., 2000). This non-ELR chemokine is unusual for
three reasons. First, it is the least understood chemokine, owing
at least in part to the fact that its receptor is still unknown. Sec-
ond, CXCL14 has an unusual primary structure (Figure 1); more
precisely, its NH2-terminal amino acid sequence preceding the
first Cys residue consists of only two amino acids (Ser-Lys). Nor-
mally, NH2-terminal regions in chemokines have five or more
residues, which are known to be important for receptor interaction
(Clark-Lewis et al., 1994). Predicted differences from “classical”
chemokines with respect to receptor-binding may explain, in part,
our current rudimentary knowledge about the role(s) played by
CXCL14 in physiological processes (see below). Third, the pri-
mary amino acid sequence of CXCL14 is highly conserved across
vertebrates as diverse as fish, birds, and mammals, suggesting an
important (non-redundant) function (Figure 1). For instance,
human and mouse CXCL14 differ only in two conservative amino
acid substitutions (Ile36→Val36 and Val41→Met41).
What is known about the function of human CXCL14? Our
studies revealed that CXCL14 is a low potent chemoattractant for
human blood monocytes (Kurth et al., 2001) whereas other groups
provided evidence for a role in DC migration (Sleeman et al., 2000;
Shellenberger et al., 2004; Shurin et al., 2005; Salogni et al., 2009).
Numerous reports have implicated CXCL14 in cancer but findings
disagree whether this chemokines displays anti-tumor as opposed
to tumor-promoting activity (Frederick et al., 2000; Shurin et al.,
2005; Ozawa et al., 2006; Wente et al., 2008; Augsten et al., 2009). A
hallmark of CXCL14 is its constitutive expression at high levels in
many epithelial tissues, most notably in the skin and gastrointesti-
nal tract (Schaerli et al., 2005; Meuter and Moser, 2008; Maerki
et al., 2009). Recent reports describe substantial expression of
CXCL14 in taste bunds of human and mouse tongues (Hevezi
et al., 2009). CXCL14 protein was also detected in rat and murine
neurons (Schmid et al., 2009; Yamamoto et al., 2011) and recently,
was proposed to be involved in inhibiting the effects of synap-
tically released GABA (Banisadr et al., 2011). Of interest, some
differences exist between humans and mice since the lung tissue of
mouse but not human stained positive for CXCL14 (Meuter and
Moser, 2008). Additional CXCL14 mRNA-positive tissues include
ovary, brain, kidney, and trachea. CXCL14 is produced highest in
keratinocytes and other epithelial cells of mucosal tissues as well as
associated macrophages. CXCL14 is not produced by leukocytes
(other than tissue macrophages) and is not found in secondary
lymphoid organs, arguing for a distinct (perhaps unique) function
in immunity. Current evidence supports the view that CXCL14 is a
homeostatic as opposed to inflammatory chemokine (Moser et al.,
2004). In fact, it appears that epidermal expression of CXCL14
is down-modulated under inflammatory conditions, arguing for
a role in tissue homeostasis rather than inflammation (Maerki
et al., 2009; Frick et al., 2011). Thus far, work with CXCL14-
deficient mice has not greatly advanced our understanding about
the function of CXCL14 (Meuter et al., 2007; Nara et al., 2007;
Tanegashima et al., 2010).
We have reported a severe breeding defect that may have
resulted from disturbed antimicrobial immunity in placenta tis-
sue or from abnormal trophoblast migration (Meuter et al., 2007;
Kuang et al., 2009). This behavior together with CXCL14 expres-
sion in taste buds of the tongue fully agree with a role of CXCL14 in
antimicrobial immunity (Hevezi et al., 2009). Indeed, our in vitro
studies have revealed that CXCL14 has broad spectrum antimicro-
bial activity for Gram-positive as well as Gram-negative bacteria,
including skin commensals as well as frequent pathogens (Maerki
et al., 2009; Table 1). CXCL14 also killed the yeast C. albicans.
CXCL14 is considerably larger than non-chemokine-AMPs; how-
ever, it shares several structural features including a high density
of positive charges at physiological pH as well as a core-structure
consisting of three anti-parallel β-strands reminiscent of the β-
defensin “fold” and a C-terminal α-helix that is typical for LL-37
(Figure 1). The antimicrobial activity in CXCL14 is sensitive to tis-
sue proteases, suggesting that the high turn-over in healthy tissues
needs to be maintained by steady-state de novo protein synthesis.
CXCL14 production is not observed in primary keratinocyte cul-
tures but is abundant in epidermis as well as artificial epidermal
equivalents, pointing to regulation by epidermal differentiation
factors (Schaerli et al., 2005). In support of a homeostatic role,
inflammatory stimuli are inhibitory and lead to down-regulation
of CXCL14 expression (Maerki et al., 2009; Frick et al., 2011).
Finally, it was recently shown that UVB radiation induced CXCL14
expression in cultured squamous carcinoma cells (Ozawa et al.,
2010) that may involve Rho family member RhoBTB2 (McKinnon
et al., 2008) and transcription factor AP-1 (Pelicano et al., 2009).
Still, our knowledge about the factors controlling CXCL14 expres-
sion in healthy epithelia and tumors is rudimentary. The model
in Figure 2 summarizes our own work with cutaneous CXCL14
but may be extended to CXCL14 at other locations with promi-
nent exposure to environmental microbes (tongue, respiratory,
gastrointestinal, and genital tracts).
We propose that CXCL14 contributes to the tonic antimicro-
bial climate made up by physical (cell impermeable epithelia)
and chemical (salt, pH, lipids) factors as well as secreted AMPs
within the outermost layer of the skin (epidermis). The antimi-
crobial activity of CXCL14 may be particularly instrumental in the
containment of “steady-state” infections, i.e., non-symptomatic
infections that occur during micro-injuries of the skin. These
frequent events remain unnoticed and, thus, do not cause inflam-
mation. This homeostatic role of CXCL14 may be supported by
other local AMPs if they are present at concentrations sufficient
for microbial killing. CXCL14 probably does not play a role in
“symptomatic” infections marked by local inflammation where
inducible factors, including inflammatory cytokines/chemokines
and inducible defensins, take over. As mentioned above, an appro-
priate model for testing the in vivo AMP activity of CXCL14 needs
to be developed.
DISCUSSION/CONCLUSION
What can we learn from the substantial body of literature deal-
ing with AMP chemokines? First, some but not all chemokines
have robust antimicrobial activity, at least during in vitro tests.
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FIGURE 2 | Antimicrobial activity of CXCL14 during superficial injuries in
human skin. During bacterial infections, Langerhans cells (LC), dermal DC
(DDC), and other sentinel cells of the skin produce inflammatory chemokines
in response to microbial stimuli, which immediately attract neutrophil and
monocytes/macrophages from circulation. DC also take up and process
microbes and emigrate to draining lymph nodes as a consequence of
microbe-induced DC maturation. Subsequent effector T cells are recruited to
the site of microbial infection. The combination of innate and adaptive
immune responses may exacerbate tissue inflammation. We propose that the
high levels of CXCL14 in the epidermis neutralize microbes that enter the skin
during micro-injuries and dermal macrophages then clean-up bacterial debris.
This instant antimicrobial system safeguards the skin from excessive cellular
immune responses, thereby contributing to the maintenance of tissue
integrity.
AMP chemokines are cationic (pI> 9.0) and have hydropho-
bic pockets and, therefore, it is reasonable to assume that they
interact with bacterial membranes. How AMPs (including AMP
chemokines) are able to discriminate between membranes of bac-
teria with those of the host cells (epithelial tissue cells) is not
completely understood. Selectivity for distinct lipid compositions
may be a possibility (Lai and Gallo, 2009), and membrane polar-
ity (or asymmetry) may also play a role. Second, chemokines are
primarily chemoattractant proteins, and it is not clear whether
the observed antimicrobial activities are secondary to the control
of leukocyte migration. For instance, the relevance of antimicro-
bial activity of inflammatory chemokines may be less important
because they are produced by local tissue cells in response to
infectious microbes that have reached numbers large enough
for triggering the inflammatory cytokine cascade. At the inflam-
matory stage (the stage at which inflammatory chemokines are
produced) chemokine-mediated recruitment of phagocytes (neu-
trophils) and, eventually, lymphocytes may be far more relevant
to infection control than direct microbial killing. Furthermore,
AMP chemokines that control adaptive immune processes, such
as CXCL9, CXCL10, and CXCL11, are frequently produced late in
infections and, thus, may be less relevant to microbial killing at the
onset of infection.
We propose that the “ideal” AMP chemokine is one that is
already present in healthy tissues or rapidly produced by local tis-
sue cells in response to microbes. We believe that CXCL14 fits
this bill since it is continuously produced at the right locations
(body-environment interfaces). Similar to inducible defensins,
neutrophil-, and perhaps monocyte-specific chemokines may also
contribute to the antimicrobial climate because of their rapid pro-
duction during infection. As mentioned above, our model of AMP
chemokines needs to be tested in appropriate infection models,
which will be one of the main tasks in future research.
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